# Poliomyelitis

> The content on this page is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. If you have health concerns, consult a qualified healthcare professional. Medova is not a medical service provider.

Source: https://medova.health/en/knowledge/diseases/polio · Language: en

## Overview

Infectious viral disease that can cause permanent paralysis. Globally on the verge of eradication — wild poliovirus type 1 remains endemic in Pakistan and Afghanistan.

## Medical Information

- ICD-10: A80
- ICD-11: 1C80
- Causative Agent: virus
- Severity: Critical
- Incubation Period: 7–21 days
- Mortality Rate: 0.05%
- Vaccine available: Yes

## Symptoms

- Paralysis (1%)
- Back pain (20%)
- Dysphagia (3%)
- Fatigue (80%)
- Fever (85%)
- Headache (75%)
- Malaise (80%)
- Myalgia (25%)
- Neck stiffness (15%)
- Shortness of breath (2%)
- Irritability (30%)
- Loss of appetite (45%)
- Nausea (40%)
- Photophobia (10%)
- Sore throat (50%)
- Vomiting (35%)
- Abdominal pain (25%)
- Constipation (20%)
- Diarrhea (15%)
- Tremor (5%)

## Transmission

- Fecal Oral (Primary route)
- Contaminated Water
- Droplet transmission
- Respiratory

## Overview

Highly infectious viral disease that can cause permanent paralysis.

## Overview

Poliomyelitis is caused by poliovirus (types 1, 2, 3), an enterovirus transmitted primarily via the fecal-oral route. Most infections are asymptomatic or cause mild illness; <1% progress to paralytic disease. The Global Polio Eradication Initiative has reduced wild poliovirus cases by >99.9% since 1988.

## Emergency Signs

Seek emergency medical care immediately if:

- Sudden weakness or paralysis of any limb — especially if asymmetric

- Difficulty breathing or swallowing

- Inability to raise the head against gravity

- Sudden severe back or neck pain with muscle weakness

- These symptoms in an unvaccinated child require urgent AFP reporting

## Detailed Symptoms

**Asymptomatic infection:** ~72% of cases

**Abortive polio (minor illness, 3–5 days):** Fever, sore throat, nausea, abdominal pain — resolves without sequelae.

**Non-paralytic aseptic meningitis:** Meningismus, muscle pain, stiffness — no paralysis.

**Paralytic poliomyelitis (<1%):** After an asymptomatic period following minor illness (biphasic fever), sudden onset of asymmetric flaccid paralysis, maximal within 2–5 days. Spinal type: limb weakness (legs > arms). Bulbar type: respiratory muscle and cranial nerve involvement — risk of respiratory failure. Post-polio syndrome can develop 15–40 years after recovery.

## Course of Disease

**Typical disease course (paralytic polio):**

1. **Incubation period:** 7–21 days (range 3–35 days).
2. **Minor illness (1–3 days):** Fever, sore throat, malaise, headache, nausea, vomiting. Resolves in ~24% of infections (abortive polio).
3. **CNS phase / major illness (1–3 days):** Recurrence of fever, headache, neck stiffness, meningeal signs. Muscle pain and spasms.
4. **Paralytic phase (hours to days):** Asymmetric flaccid paralysis, typically legs > arms. Maximal paralysis usually develops within 3–4 days. Proximal > distal. No sensory loss (pure motor).
5. **Recovery (weeks to months):** Maximum recovery within 6 months. Strength may continue to improve slowly for up to 2 years.

**Spinal vs. bulbar:** Spinal polio (limb paralysis) is most common. Bulbar polio involves cranial nerves and respiratory center — medical emergency.

## Diagnosis

Suspect polio in any child <15 years with acute flaccid paralysis (AFP) or any age person with AFP in endemic/outbreak setting. Confirmation:

- Stool culture: poliovirus isolation (gold standard) — two specimens 24 hours apart, within 14 days of paralysis onset

- CSF analysis: lymphocytic pleocytosis, normal glucose, elevated protein

- Serology: not routinely used

- EMG: lower motor neuron pattern
All AFP cases must be reported to national health authorities (polio-free zones) and WHO.

## Treatment

No specific antiviral treatment is available for poliomyelitis. Management is supportive:

- **Acute phase:** analgesics, complete bed rest; hot packs for muscle spasm relief

- **Respiratory support:** mechanical ventilation for bulbar or respiratory involvement

- **Physiotherapy:** early passive range-of-motion exercises during acute phase; intensive rehabilitation during recovery phase

- **Long-term rehabilitation:** orthotics, surgical correction of deformities, assistive devices

- **Post-polio syndrome:** energy conservation, pain management, non-fatiguing exercise programs

## Prevention Details

Two highly effective vaccines are available:

- **Inactivated Polio Vaccine (IPV):** injectable

- no risk of vaccine-derived polio

- used in polio-free countries

- **Oral Polio Vaccine (OPV):** live-attenuated

- provides intestinal immunity

- rare risk of vaccine-derived poliovirus (VDPV) — being phased out
WHO recommended schedule: IPV at 2, 4, 6–18 months, and 4–6 years. Booster for travelers to endemic/outbreak areas.
Travelers to Pakistan, Afghanistan, or areas with circulating vaccine-derived poliovirus should receive a booster IPV dose within 4 weeks to 12 months before departure (required by GPEI exit requirements for residents/long-term visitors of endemic countries).

## Travel Advice

- Check polio vaccination status before all international travel.

- **Travelers to Pakistan, Afghanistan, or cVDPV-affected areas:** require proof of IPV vaccination (within 4 weeks to 12 months before departure from endemic country). Some countries require documentation on the International Certificate of Vaccination.

- Travelers from endemic countries may be required to show proof of vaccination at borders.

- Practice strict hand hygiene and food/water safety in areas with inadequate sanitation.

## How common is it?

Since the Global Polio Eradication Initiative (1988), wild poliovirus cases fell from ~350,000/year to 6 (WPV1) reported in 2021. Wild poliovirus type 2 eradicated in 1999; type 3 in 2019. WPV1 remains endemic in Pakistan and Afghanistan. Circulating vaccine-derived poliovirus (cVDPV) outbreaks occur in areas with low OPV coverage, including parts of Africa, Middle East, and Asia. Over 200 countries have maintained polio-free status.

## Risk Factors

**Host factors increasing risk of paralytic disease:**

- **Age:** Risk of paralysis increases with age at infection. Adults develop paralytic polio more frequently and with greater severity than children.

- **Immunodeficiency:** Primary immunodeficiency (especially B-cell defects such as agammaglobulinemia) dramatically increases risk of paralytic disease and chronic infection. These individuals can excrete vaccine-derived poliovirus for years (immunodeficiency-associated VDPV, iVDPV).

- **Pregnancy:** Pregnant women have a higher incidence of paralytic polio and higher case-fatality rates.

- **Tonsillectomy:** Prior tonsillectomy increases risk of bulbar polio.

- **Intramuscular injections:** Injections in the weeks before or during infection increase risk of paralysis in the injected limb ("provocation polio").

- **Strenuous physical exercise:** Physical exertion during the incubation period or early illness is associated with increased severity of paralysis.

**Environmental and geographic risk factors:**

- **Lack of vaccination:** Unvaccinated or under-vaccinated individuals in any country are at risk. Immunity gaps from missed routine immunization are the primary driver of cVDPV outbreaks.

- **Poor sanitation:** Fecal contamination of water supplies facilitates transmission.

- **Conflict and displacement:** Disruption of immunization programs in conflict zones (Afghanistan, Pakistan, parts of Africa) sustains transmission.

- **Overcrowding:** Close living conditions in camps or urban slums increase exposure risk.

**Travel-related risk factors:**

- Travel to endemic countries (Afghanistan, Pakistan) or countries with active cVDPV outbreaks

- Extended stays in rural areas with poor sanitation infrastructure

- Visiting friends and relatives (VFR) travelers may underestimate risk and delay vaccination

## Complications Details

- **Permanent flaccid paralysis:** asymmetric limb weakness, most commonly legs; occurs in <1% of infections but leaves lifelong disability

- **Respiratory failure:** bulbar polio or high cervical spinal cord involvement; historically required iron lung

- **Post-polio syndrome (PPS):** gradual onset of new muscle weakness, fatigue, pain 15–40 years after initial infection, affecting ~25–40% of paralytic polio survivors

- **Secondary musculoskeletal complications:** scoliosis, joint deformities due to muscle imbalance

- **Psychological impact:** chronic disability, depression, social isolation

## Recovery & Outlook

**Asymptomatic infection:** 72% of cases. No sequelae.

**Abortive polio (minor illness):** 24%. Complete recovery.

**Non-paralytic aseptic meningitis:** 1–5%. Full recovery within 2–10 days.

**Paralytic polio:** 0.5–1% of infections.

- CFR: 2–5% in children, 15–30% in adults (respiratory muscle involvement).

- Bulbar polio (brainstem involvement): CFR 25–75%.

- Partial or complete recovery of paralysis in 60% over 6–12 months. Residual paralysis is permanent.

- Post-polio syndrome: 25–40% of paralytic polio survivors develop new weakness, fatigue, and muscle atrophy 15–40 years later.

## Available Vaccines

- [Polio IPV Vaccine](https://medova.health/en/knowledge/vaccines/polio-ipv-vaccine)
- [Oral Polio Vaccine](https://medova.health/en/knowledge/vaccines/oral-polio-vaccine)

## Sources & content verification

- Data sources: WHO/ICD-11, CDC, GPEI (SafeTripVax QMR-003, 2026-02-25), WHO Disease Factsheets 2024 + CDC Travelers' Health 2024 + Heymann CDD 21st ed., WHO Disease Factsheets 2024 + CDC Yellow Book 2024 + Heymann CDD 21st ed.
- Generated by: AI + Human review
- Review status: Awaiting medical review
- Last updated: 2026-02-25
- [www.who.int](https://www.who.int/emergencies/disease-outbreak-news)
- [www.who.int](https://www.who.int/news-room/fact-sheets)

---

The content on this page is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. If you have health concerns, consult a qualified healthcare professional. Medova is not a medical service provider.

[Full terms of use](https://medova.health/en/terms)
